¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"initial dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • dose rate effect
    ¼±·®·üÈ¿°ú
  • dose rate meter
    ¼±·®·ü°è, ¼±·®·üÃøÁ¤±â
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
  • exit dose
    Åë°ú¼±·®
  • exposure dose
    Æø·Î¼±·®
  • effective dose
    1. À¯È¿¿ë·® 2. À¯È¿¼±·®
  • effective dose equivalent
    À¯È¿¼±·®ÇØ´ç·®
  • erythema dose
    È«¹Ý¼±·®
  • fatal dose
    1. Ä¡»ç¿ë·® 2. Ä¡»ç¼±·®
  • fractional dose
    1. ºÐÇÒ¿ë·® 2. ºÐÇÒ¼±·®
  • high dose rate
    °í¼±·®·ü
  • high dose rate intraluminal radiotherapy
    °í¼±·®·ü°ü³»¹æ»ç¼±Ä¡·á
  • high dose tolerance
    Ç׿ø°ú·®Çã¿ë
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • curative dose
    Ä¡À¯¿ë·®, Ä¡À¯¹æ»ç¼±·®
  • depth dose curve
    ½ÉºÎ¼±·®°î¼±
  • dose-response curve
    ¿ë·®¹ÝÀÀ°î¼±
  • percentage depth dose curve
    ½ÉºÎ¼±·®¹éºÐÀ²°î¼±
  • sigmoid dose-response curve
    ±¸ºÒ¼±·®¹ÝÀÀ°î¼±
  • dose
    ¿ë·®, Åõ¿©·®, ¹æ»ç¼±·®
  • depth dose
    ½ÉºÎ¼±·®
  • dose distribution
    ¹æ»ç¼±·®ºÐÆ÷
  • dose profile
    ¹æ»ç¼±·®Ãø¸éµµ
  • dose rate
    ¼±·®·ü
  • dose rate effect
    ¼±·®À²È¿°ú
  • dose rate meter
    ¼±·®À²°è, ¼±·®·üÃøÁ¤±â
  • dose rate variation
    ¼±·®·üº¯ÀÌ
  • dose response relationship
    ¿ë·®¹ÝÀÀ°ü°è
  • doubling dose
    ¹è°¡¼±·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • initial tetanus
    Ãʰ­Ãà(ôøË­õê).
  • initial twitch
    Ãʱâ´Ü¼öÃà.
  • initial urine
    Ãʱⴢ.
  • initiator =initial explosive
    ±âÆøÁ¦, °³½Ã(ÀÎ)ÀÚ.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®, Áß°£À¯È¿·®.
  • ED 50=£¾effective dose 50%
    50% À¯È¿·®.
  • ED 50=ÊÝeffective dose 50%
    50% À¯È¿·®.
  • ED=ÊÝeffective dose
    À¯È¿·®.
  • ID50 (50% infectious dose)
    50% °¨¿°·®
  • LD = lethal dose
    Ä¡»ç·®.
  • LD50 (50% lethal dose)
    50% Ä¡»ç·®
  • LD= lethal dose
    Ä¡»ç·®.
  • MED => minimum effective dose
    ÃÖ¼ÒÈ«¹Ý·®
  • MED=> minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
  • MED=£¾minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • initial reaction
    Ãʱâ¹ÝÀÀ.
  • initial segment
    ÃÊÀý(ôøï½).
  • initial segment
    ½ÃÀÛºÐÀý
  • initial setting
    ÃʱâÀÀ°á.
  • initial stage
    Ãʱâ(ôøÑ¢), Àϱâ(ìéÑ¢).
  • initial symptom
    ÃʱâÁõ»ó(ôøÑ¢ñøßÒ).
  • initial tetanus
    Ãʰ­Ãà(ôøË­õê).
  • initial twitch
    Ãʱâ´Ü¼öÃà.
  • initial urine
    Ãʱⴢ.
  • initiator =initial explosive
    ±âÆøÁ¦, °³½Ã(ÀÎ)ÀÚ.
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose
    Èí¼ö·®.¹æ»ç¼±Èí¼ö¼±·®(ýåâ¥àÊåÖ).
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
CIC cardioinhibitor center; circulating immune complex; clean intermittent catheterization; completely i...
ILB infant, low birth [weight]; initial lung burden
IPS idiopathic pain syndrome; idiopathic postprandial syndrome; inches per second; infundibular pulmonar...
ISI infarct size index; initial slope index; injury severity index; Institute for Scientific Information...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DEF Dose Effect Factor
DI Dose Intensity
DMF Dose Modifying Factor
DRF Dose Reduction Factor
DAP Dose area product
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dose rate effect
    ¼±·®À² È¿°ú
  • dose rate variation
    ¼±·®·ü º¯È­
  • dose response relationship
    ¹æ»ç¿ë·® ¹ÝÀÀ °ü°è, ¿ë·® ¹ÝÀÀ °ü°è
  • dose-effect relationship
    ¼±·® ¿µÇâ °ü°è
  • dose-equivalent limit
    ¼±·® ´ç·® Çѵµ
  • dose-response curve
    ¿ë·® ¹ÝÀÀ °î¼±
  • dose-volume histogram
    ¼±·® üÀû È÷½ºÅä±×¶÷, ¼±·® üÀûÇ¥
  • effective dose 50%
    Áß°£ À¯È¿·®, 50% À¯È¿·®
    µ¿¹°¿¡ µ¶¼Ò³ª ¾à¹° Åõ¿© ½Ã, 50%ÀÇ µ¿¹°¿¡¼­ À¯È¿ÇÏ´Ù°í ÃßÁ¤µÇ´Â ¿ë·®.
  • equivalent dose
    µî°¡ ¼±·®
  • equivalent uniform dose
    µî°¡ ±ÕÁú ¼±·®
  • erythema dose
    Èï¹Ý ¼±·®
  • exposure dose
    Á¶»ç·®
  • high dose tolerance
    °í¿ª ¿ªÄ¡
  • immunizing dose
    ¸é¿ª·®
  • intoxicating dose
    Áßµ¶·®, Áßµ¶ ¼±·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
shocking dose In experimental anaphylaxis, the inoculum of antigen that causes anaphylactic shock in an animal sensitised by a previous inoculum (sensitizing dose) of the same antigen.
(05 Mar 2000)
skin dose The quantity of radiation delivered to the skin surface.
(05 Mar 2000)
daily dose The total amount of a remedy that is to be taken within 24 hours.
(05 Mar 2000)
depth dose The dose of radiation at a distance beneath the surface, including secondary radiation or scatter, in proportion to the dose at the surface.
(05 Mar 2000)
divided dose A definite fraction of a full dose; given repeatedly at short intervals so that the full dose is taken within a specified period, usually one day.
Synonym: fractional dose.
(05 Mar 2000)
dose 1. <pharmacology> A quantity to be administered at one time, such as a specified amount of medication.
2. <radiobiology> A general term denoting the quantity of radiation or energy absorbed. For special purposes it must be appropriately qualified. If unqualified, it refers to absorbed dose. Unit of absorbed dose is the rad. The SI unit is the gray (1 Gy = 1 J kg-1 = 100 R).
Origin: Gr. Dosis = a giving
(16 Dec 1997)
dose-effect curve This is a graph drawn to show the relationship between the dose of a drug or other chemical and the magnitude of the graded effect that it produces.
(09 Oct 1997)
dose-escalation A preliminary clinical trial in which the amount of the drug is either periodically increased or increased with each new trial arm that is added. Used to determine how a drug is tolerated in people.
(09 Oct 1997)
dose fractionation Adminstration of the total dose of radiation (radiation dosage) in parts, at timed intervals.
(12 Dec 1998)
dose intensity In chemotherapy, the total amount of drug delivered in a one-week period. Can be given all at once or over a period of several days.
(16 Dec 1997)
dose-ranging A preliminary clinical trial in which the amount of the drug is either periodically increased or increased with each new trial arm that is added. Used to determine how a drug is tolerated in people.
(09 Oct 1997)
dose-response curve This is a graph to show the relation between the dose of a drug or other chemical and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(09 Oct 1997)
dose-response relationship Relationship in which a change in the amount, intensity, or duration of exposure is associated with a change in risk of a specified outcome.
(05 Mar 2000)
dose-response relationship, drug The relationship between the dose of an administered drug and the response of the organism to the drug.
(12 Dec 1998)
dose-response relationship, immunologic A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á